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Biological context
Protein activation via tyrosine phosphorylation by
tyrosine kinases and the concomitant deactiva-
tion/dephosphorylation by protein tyrosine phos-
phatases (PTPs) plays a central role in cellular sig-
naling. Tyrosine phosphorylation regulates cell home-
ostasis by the control of gene-transcription, cell-cycle
progression, cell growth, cell metabolism, immune
response as well as programmed cell death (Walton
et al., 1993; Zhang, 2002). Due to the low level
of cellular phosphotyrosine these pathways and the
respective enzymes were identified only rather re-
cently: the first tyrosine kinase src by Hunter et al.
(1980), the first protein tyrosine phosphatases by Nel-
son and Branton (1984). Receptor tyrosine kinases
include the insulin receptor and a large variety of other
growth factor receptors. Examples of PTPs include
cdc25A responsible for cell cycle progression, CD45
activating B- and T-cells, the Vaccinia virus minimal
variant VH1, YOP 2b required for the virulence of
the pathogenic Yersinia genus of bacteria, and PTP1B,
which is a potential target for diabetes and obesity
treatment.
PTP1B can dephosphorylate a number of tyrosine
kinases in vitro and in cell culture at the endoplasmic
reticulum (ER) (Haj et al., 2002). In vivo specificity
of this phosphatase for insulin receptor dephospho-
rylation was suggested by the finding that the active
site mutant C215S copurifies with insulin receptors
from eucaryotic cell lines (Seely et al., 1996; Bandy-
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opadhyay et al., 1997). Association with the activated
insulin receptor is mediated by three tyrosine residues
in the catalytic domain that become phosphorylated
upon insulin treatment (Bandyopadhyay et al., 1997).
The importance of PTP1B in the regulation of glucose
metabolism was underlined by the finding that ho-
mozygous PTP1B knockout in mice leads to strongly
increased blood glucose clearance and hypersensitiv-
ity to insulin (Elchebly et al., 1999). Additionally,
homo- and heterozygous knockouts proved to decrease
weight gain by 50% on high fat diet. For these rea-
sons, PTP1B appears as an attractive target for specific
inhibitors that would counteract type II diabetes and
obesity.
Full length human PTP1B consists of 435 residues.
It encompasses the highly conserved 298 amino acid,
N-terminal catalytic domain (PTP1Bcat), a proline rich
domain and a C-terminal hydrophobic anchor that tar-
gets the protein to the membrane of the ER (Frangioni
et al., 1992; Haj et al., 2002). The crystal structure
of the PTP1Bcat construct 1-321 (Barford et al., 1994)
shows that this domain consists of 12 β-strands and 8
α-helices. The catalytic residue C215 is located near
the surface in a crevice between β12 and α4. Here
we report the NMR resonance assignments of the con-
served 298 amino acid PTP1Bcat domain in complex
with the peptidic Novartis inhibitor CGS35385.
Methods and experiments
Human PTP-1B (1-298) was cloned from a human
hippocampal cDNA library (Clonetech) using PCR
and placed into a pET 19-b vector (Novagen). Re-
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Figure 1. 1H-15N TROSY spectrum of PTP1Bcat at 293 K.
combinant, uniformly 2H (∼ 60%), 15N (> 95%), 13C
(> 95%) labeled PTP1Bcat was expressed in E. coli
strain BL21 (DE3), and the soluble protein was pu-
rified by cation followed by anion exchange chro-
matography. A 500 µl NMR sample was prepared
containing 0.5 mM PTP1Bcat, 1 mM peptidic inhibitor
CGS35385 (DADEXLIP-amide, X = phenylalanine-
p-difluoromethyl phosphonate), 25 mM TRIS-d11,
10 mM DL-1,4-DTT-d10, 0.02% sodium azide,
50 mM NaCl, 95% H2O/5% D2O at pH 7.5. The NMR
tube was flame-sealed under nitrogen. PTP1Bcat tends
to aggregate at concentrations higher than 0.5 mM and
temperatures above 293 K. Peak dispersion was im-
proved at pH 7.5 relative to pH 6.5. All spectra were
recorded on Bruker DRX 600 and 800 spectrometers
at 293 K. Assignments were derived from standard
and TROSY versions of HN(CO)CA, HN(CA)CO,
HN(CO)CACB, HNCACB, HNCA, HNCO, and 15N-
edited NOESY experiments. 1H, 15N, and 13C chemi-
cal shifts were referenced relative to the frequency of
the 2H lock resonance of water.
Extent of assignment and data deposition
The assignments comprise 78% of all 1HN, 15N, 13C′,
13Cα and 13Cβ resonances covering 244 of the 285
non-proline residues. Due to intermediate conforma-
tional exchange, almost all of the resonances for the
remaining residues were broadened beyond detection
in the three-dimensional spectra. A map of the miss-
ing assignments onto the crystal structure reveals that
most of these residues surround the active site whereas
a few others are located in turn and loop regions.
Apparently, the active site undergoes conformational
exchange despite the presence of the high affinity in-
hibitor CGS35385 (IC50 = 100 nM). Very likely, this
apparent plasticity of the active site is linked to the
ability of PTP1B to accommodate a large variety of
pTyr-containing substrates and the large structural re-
arrangements of the active site observed upon ligand
binding (Zhang, 2002). Despite the difficulty in ob-
serving the active site, the assignments include at least
9 key residues (Y46, R47, D48, D181, F182, R254,
R257, Q262, Q266) involved in substrate binding and
turnover (Zhang, 2002). Chemical shifts have been de-
posited in the BMR data bank under accession number
5474.
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